Lovaza's Effect on Clopidogrel in a Neuro Population

Inclusion Criteria: * Gender: Male and female * Age range: 25 - 80 years of age * Study population: Patients who require antiplatelet therapy with clopidogrel +/- aspirin who are candidates for neuroendovascular stenting or have had an ischemic stroke/TIA. * Eligible females will be: Non-pregnant nor lactating/breastfeeding; Be surgically sterile for at least 6 months, postmenopausal, or if heterosexually active and of childbearing potential, agree to continue to use an accepted method of birth control throughout the study. Exclusion Criteria: * Any clinically significant abnormal finding uncovered during the physical examination and/or clinically significant abnormal laboratory result at screening according to the clinical judgment of the Investigators * Current alcohol abuse * Smokers unable to refrain from smoking during the clinical trial * Patients who are already taking anticoagulants or other antiplatelets (ticlopidine, prasugrel, dipyridamole, cilostazol), or patients already taking PUFAs * Patients taking medications known to interact with clopidogrel that cannot be held or changed due to increased risk of adverse health events. * Cytochrome P450 3A4 and 2C19 (CYP3A4, CYP2C19) inhibitors or substrates known to cause competitive inhibition * Proton pump inhibitors (PPIs) * NSAIDs * Pregnant women or lactating/breastfeeding women. * Active or recent major bleeding (within 14 days) using TIMI score (minor severity will be acceptable based on clinical examination/patient history) * Major severity- * Intracranial hemorrhage * Cardiac tamponade * Overt bleeding with a decrease in hemoglobin ≥ 5 g/dl or a decrease in hematocrit ≥ 15% (with or without an identifiable site) * Minor severity- * Spontaneous gross hematuria * Spontaneous hematemesis * Spontaneous hemoptysis * Observed bleeding with decrease in hemoglobin ≥ 3 g/dl but ≤ 5 g/dl (with an identifiable site) * History of gastric or duodenal ulcer * Platelet count \< 100 x 109/L * Serum creatinine \> 2 mg/dL * Liver injury (alanine transaminase level \> 1.5 times upper limit of normal) * Recent surgery (within 14 days of study screening) * Known bleeding diathesis including but not limited to * Hemophilia * Von Willebrand disease * Leukemia * Clotting factor deficiencies * Uncontrolled hypertension * Sustained systolic blood pressure \> 185 mmHg, despite treatment * Sustained diastolic blood pressure \> 110 mmHg, despite treatment * Hypersensitivity or intolerance to clopidogrel, aspirin, PUFAs and/or documented fish allergy * Patients who are currently enrolled in a different study or who have taken an investigational medication 30 days prior to starting this study.